InvestorsHub Logo
Followers 38
Posts 2976
Boards Moderated 0
Alias Born 01/14/2003

Re: Dancing in the dark post# 296724

Saturday, 09/05/2020 1:46:57 PM

Saturday, September 05, 2020 1:46:57 PM

Post# of 426546
Sorry to quote myself, but I had an additional thought

"Instead of partnering with BP for branded vascepa reduce-it indication in US, how about partnering with teva/apotex for "authorized" generic icosapent ethyl?
Under a royalty bearing license agreement ... "

Ultimately, what we want here, instead of amarin vs. generics, is generics vs. generics.

If amarin IP-licenses reduce-it indication to some generic manufacturers and other non IP-licensed manufacturers begin selling generic icosapent ethyl, the licensed IP manufacturers will themselves police the non licensed IP manufacturers.

It's the ratio, baby ... the EPA/AA ratio!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News